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-CLLs with bimodal CD49d expression account for ~20% of CLL and display distinct clinico-
biological features. 




CD49d is a remarkable prognostic biomarker of chronic lymphocytic leukemia (CLL). The 
extensively validated 30% of positive CLL cells cut-off value is able to separate CLL patients into 
two subgroups with different prognosis, but it does not consider the pattern of CD49d expression. In 
the present study, we analysed a cohort of 1,630 CLL samples and identified the presence of ~20% 
of CLL cases (n=313) characterized by a bimodal expression of CD49d, i.e. concomitant presence 
of a CD49dpos sub-population and a CD49dneg sub-population. At variance with the highly stable 
CD49d expression observed in CLL patients with a homogeneous pattern of CD49d expression, 
CD49d bimodal CLL showed a higher level of variability in sequential samples, and an increase in 
the CD49dpos sub-population over time after therapy. The CD49dpos sub-population from CD49d 
bimodal CLL displayed higher levels of proliferation compared to the CD49dneg cells, was more 
highly represented in the bone marrow compared to peripheral blood (PB), and in PB CLL subsets 
expressing the CXCR4dim/CD5bright phenotype, known to be enriched in proliferative cells. From a 
clinical standpoint, CLL patients with CD49d bimodal expression, regardless of whether the 
CD49dpos sub-population exceeded or not the 30% cut-off, experienced a clinical behavior similar 
to CD49dpos CLL, both in the chemo-immunotherapy (n=1,522) and in the ibrutinib (n=158) 
settings. Altogether, these results suggest that CD49d can drive disease progression in CLL, and 
that the pattern of CD49d expression should be also considered to improve the prognostic impact of 




CD49d, the rate-limiting alpha chain of the CD49d/CD29 integrin heterodimer very late antigen-4 
(VLA-4), expressed in ~40% of chronic lymphocytic leukemia (CLL) cases, is a strong independent 
predictor of survival and treatment need in CLL.1-6 
 
CD49d/CD29 mediates both cell-cell and cell-matrix interactions in CLL-involved tissues, 
delivering pro-survival signals and protecting CLL cells from drug-induced apoptosis.7 Moreover, 
CD49d/CD29 has a key role in driving homing of CLL cells to lymphoid tissues.8,9 This is 
confirmed by the association between high CD49d expression and the presence of 
lymphadenopathy at diagnosis, the development of lymphadenopathy during the course of the 
disease, and the almost universal CD49d expression in CLL subsets with prevalent nodal disease.10-
12 Lymph-nodes (LNs) represent the predominant sites of CLL cell activation and proliferation.13,14 
Concordantly, LN-derived CLL cells are characterized by a distinct gene expression profile and 
phenotype, including higher CD49d expression than in paired peripheral blood (PB) samples.8,15 A 
higher CD49d expression was also documented in PB CXCR4low/CD5bright CLL cells, a cell subset 
representing the proliferative LN-derived CLL cell fraction.8,16 
 
In CLL, CD49d expression is variable, from completely negative cases to cases uniformly 
expressing the molecule at very high levels.17-19 The 30% cut-off, which robustly separates CLL 
patients into two subgroups with different prognosis, has been extensively validated.1-5 However, 
the simple use of the cut-off does not provide information on the expression pattern of CD49d. 
Indeed, we previously observed that CD49d may be expressed in a bimodal pattern in CLL, with the 
co-presence of clearly distinct negative and positive groups of cells in the same sample.20,21 In this 
context, CD49dpos sub-populations, especially when represented in <30% of cells, raises the 
question whether they may or may not impact disease progression.  
 
Here, we analysed CD49d expression in a large cohort of CLL cases with the following aims: i) 
determine the exact frequency of CLL cases with a bimodal pattern of CD49d expression; ii) 
highlight potential functional differences between the CD49dneg and CD49dpos cells in CLL 






CLL patients and primary CLL cell characterization 
The study, performed under the IRB approval of the Aviano Centro di Riferimento Oncologico 
(Approvals n. IRB-05-2010 and n. IRB-05-2015), included 1,630 CLL diagnosed and treated 
according to the current iwCLL guidelines,22 from a consecutive series of 2,045 multicenter patients 
all referred to the Clinical and Experimental Onco-Hematology Unit of the Centro di Riferimento 
Oncologico in Aviano for immunocytogenetic analyses between 2006 and 2017. For the purposes of 
clinical analyses, patients were split in two cohorts: cohort A (764 patients from a single center) and 
cohort B (866 patients from 5 different centers), whose clinical and biological features are 
summarized in Supplemental Table 1. This study also included 158 CLL patients (47 cases 
relapsed/refractory [RR] CLL from the cohort of 1,630, and additional 88 RR and 23 treatment-
naïve [TN] CLL) treated with ibrutinib in the context of a multi-center Italian named patient 
program (NPP); clinical and biological features of this cohort are summarized in Supplemental 
Table 2. Informed consent was obtained in accordance with the Declaration of Helsinki. Patients’ 
characterization included IGHV mutational status, cytogenetic abnormalities, TP53 and NOTCH1 
mutations, all detected as previously reported,2,23-27 and clinical parameters, such as age, Rai stage, 
beta-2-microglobulin (B2M) levels. 
  
Immunophenotypic analyses, cell sorting, proliferation assay and telomere length 
measurements 
Immunophenotypic analyses and cell sortings were performed on fresh peripheral blood (PB), or 
paired PB and bone marrow (BM) samples at different time points utilizing a FACSCantoI and a 
FACSAriaIII (BD Biosciences, La Jolla, CA, USA) flow cytometer/cell sorter upon instrument 
calibration with CS&T beads (BD Biosciences) using the FACSDiva software (BD Biosciences). 
Detailed guidelines for the analysis and definition of CD49d bimodal expression28 are reported in 
Supplemental materials. 
 
Proliferation and telomere length assays were performed using previously published procedures.29,30 







Frequency of CD49d bimodal expression in CLL 
CD49d expression was analysed in PB samples from 1,630 CLL cases at diagnosis (Supplemental 
Table 1). According to the 30% cut-off identified for clinical purposes,1,2 904 cases (55.5%) were 
CD49dneg and 726 cases (44.5%) were CD49dpos. In 313 cases (19.2%), CD49d had a bimodal 
expression (bimCD49d), with two separate cell populations, one completely negative, with a 
fluorescence signal superimposable to that of the negative control, and the other positive, 
characterized by a fluorescence signal completely above the cut-off (Figure 1A and Supplemental 
Figure 1). CLL cells from the remaining 1,317 patients (80.8%) expressed CD49d in a 
homogeneous pattern (homCD49d) (Figure 1B). In terms of percentage of CD49d-expressing CLL 
cells, virtually all values (ranging from 1% to 99%) were represented both in the bimCD49d and 
homCD49d group. However, while in bimCD49d cases all CD49d expression values were almost 
equally represented, 90% of CLL with homCD49d expression showed either very low (56% of 
cases with expression <20% CD49d) or very high (34% cases with expression >80% CD49d) 
expression levels, with as low as 2% of cases clustered around the 30% cut-off (Figure 1C and 1D), 
in keeping with previous observations.1,2 Of note, the vast majority of cases expressing CD49d 
around the 30% cut-off (CD49d expression ranging between 20% and 40%) belonged to the 
bimCD49d group (67/94 cases, 71%). 
 
The CD49dneg and CD49dpos cell sub-populations from bimCD49d CLL derive from the same 
clone 
The IGHV mutational status was assessed by Sanger sequencing in 303 bimCD49d. In 283/303 
(93.4%) cases, a unique IGHV sequence was detected, whereas among the remaining 20 cases either 
multiple IGHV sequences were found (n=14) or no IGHV sequence could be determined (n=6). A 
detailed description of the IGHV gene usage and status is reported in Supplemental Table 3. The 
IGHV sequence analysis was then repeated by NGS in the sorted CD49dneg and CD49dpos fractions 
from 31 bimCD49d samples with variable amount of CD49dpos sub-population, including one bi-
clonal sample presenting two different immunoglobulin rearrangements by Sanger sequencing. 
NGS analysis confirmed a unique IGHV sequence in both CD49dneg and CD49dpos fractions in 30 
cases, and the concomitant presence of two sequences in the bi-clonal sample, without differences 





The proportion of the CD49dpos sub-population in bimCD49d CLL tends to increase over time 
Sequential samples were available in 94 bimCD49d and in 322 homCD49d patients (median sample 
interval: 34 months [range 3-116] for bimCD49d, and 35 months [range 6-161] for homCD49d). 
Forty-two (44.7%) and 131 (40.7%) patients from the bimCD49d and homCD49d groups 
respectively had received one line of therapy after the first sampling, whereas the remaining 
patients received no treatment before the two samplings.  
 
Compared to homCD49d CLL, where CD49d expression was highly stable over time 
(Supplemental Figure 2AB), bimCD49d cases were characterized by a higher variability of CD49d 
expression between the first and the second sample (Supplemental Figure 2CD). Despite this, the 
proportion of CD49dpos cells, almost stable between the first and the second sample in untreated 
bimCD49d cases (Figure 2A), increased after the first line of treatment (p=0.03) (Figure 2B). 
Moreover, a detailed analysis of CD49d expression in sequential samples from additional 
bimCD49d CLL patients receiving two to four lines of therapy (n=13; median sample intervals= 33 
months), highlighted an increasing proportion of CD49dpos cells with a tendency towards plateau as 
the number of treatment lines increased (Figure 2C). 
 
The proportion of CD49dneg and CD49dpos cell sub-populations varies among different tissue 
compartments  
The proportion of CD49dneg and CD49dpos sub-populations was analysed in paired PB and BM 
samples from 13 bimCD49d cases. A higher amount of CD49dpos cells was observed in BM 
compared to PB samples (p=0.0006). Notably, in 3 cases the CD49dpos subset increased from <30% 
in the PB to >30% in the BM (Figure 3A). 
 
We next analysed the amount of CD49dpos cells in the context of subpopulations with variable 
reciprocal densities of CXCR4/CD5 (Supplemental Figure 3), representing cell subsets defined as 
“recent emigrants from tissue sites” (CXCR4dim/CD5bright) or “attempting to re-enter the tissue sites” 
(CXCR4bright/CD5dim)16 in 147 bimCD49d CLL. A median of 8% (range 3-35%) and 7% (range 3-
14%) of total CLL populations was identified as CXCR4dim/CD5bright and CXCR4bright/CD5dim, 
respectively. Overall, the CXCR4dim/CD5bright fractions were characterized by significantly higher 






CD49dpos cells display a higher propensity to proliferate than CD49dneg cells 
The CXCR4dim/CD5bright cell fraction is known to mark CLL subsets with increased proliferation 
compared to CXCR4bright/CD5dim cells.16 Consistently, proliferation experiments using cells from 
bimCD49d CLL (n=10), evidenced a higher proportion of proliferating cells in the CD49dpos 
compared to the CD49dneg fractions (p=0.004) (Supplemental Figure 4A-B), and no acquisition or 
loss of CD49d expression by the CD49dneg and CD49dpos fractions respectively (Supplemental 
Figure 5). 
 
We next examined the telomere length in paired CD49dneg and CD49dpos sub-populations from 15 
CLL samples (Supplemental Figure 6). Despite an intra-clonal variation in the length of individual 
telomeres, all sub-populations tested showed overall short telomeres, indicating that they had 
undergone a large number of cell divisions,31 without substantial differences between the paired 
CD49dpos and CD49dneg cells (mean telomere length 3.1 kb and 3.2 kb, respectively). Of note, in 
two cases (CLL#7 and CLL#8, Supplemental Figure 6, arrows) the CD49dpos sub-populations 
displayed shorter telomeres (>1 kb difference) compared to the CD49dneg cells suggesting a greater 
proliferative history for the CD49dpos cell fractions. 
 
Finally, we performed a comprehensive cytogenetic and mutation analysis in the sorted CD49dneg 
and CD49dpos cell fractions from 56 bimCD49d CLL cases characterized by one or more genetic 
abnormalities (75 total tests).4,32 In this context, significant associations between CD49dpos cells 
with trisomy 12 and NOTCH1 mutations, as previously described by us,20,21 and between CD49dneg 
cells and 17p deletion, were detected (Supplemental Tables 4-5). 
 
CLL patients with CD49d bimodal expression have a clinical behavior similar to CD49dpos 
CLL in the context of standard chemo-immunotherapy 
To study the clinical behavior of bimCD49d CLL in terms of overall survival (OS), CLL cases were 
split in two homogeneous cohorts (cohort A and cohort B, see Methods and Supplemental Table 1). 
To exclude a potential bias due to improved survival for patients treated with novel agents including 
ibrutinib, only patients treated with standard chemo-immunotherapy were included in these analyses 
(n= 1,522). 
 
Notably, when comparing the clinical outcomes of bimCD49dneg (i.e. with a CD49dpos component 
<30% cut-off) and bimCD49dpos (i.e. with a CD49dpos component >30% cut-off) CLL, no OS 
differences were found in the separate and combined cohorts (Supplemental Figure 7A-B and 
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Figure 4A). Moreover, no other cut-off values able to split bimCD49d cases into two groups with 
different OS could be selected by ROC curve analyses (Supplemental Figure 8A-B). Conversely, 
the main clinical and biological parameters showed the expected trends of OS in both cohorts 
(Supplemental Figure 9). Given the superimposable clinical behavior of bimCD49dneg and 
bimCD49dpos CLL, we merged them in a single group and compared their OS probabilities with 
those of homCD49d CLL split according to the 30% cut-off. BimCD49d cases displayed 
significantly shorter OS compared to homCD49dneg CLL (p<0.0001 for cohort A, p=0.0013 for 
cohort B, and p<0.0001 for the combined cohort), and no difference with homCD49dpos CLL in 
both the separate and combined cohorts (Supplemental Figure 7C-D and Figure 4B). 
 
The same analyses were performed using the treatment-free survival (TFS) readout. The results 
obtained, overall similar to those obtained using the OS readout, are summarized in Supplemental 
Figures 10-12. 
 
CD49d bimodal expression has independent prognostic impact in patients treated with 
standard chemo-immunotherapy 
To test the independent prognostic impact of bimCD49d expression, patients were split in three 
groups: homCD49dneg, homCD49dpos and bimCD49d. As summarized in Supplemental Table 6, the 
frequency of various negative clinical and biological features in bimCD49d CLL was usually 
intermediate between that observed in homCD49dneg and homCD49dpos CLL, with the exclusion of 
del17p/TP53disruption that showed the lowest frequency in bimCD49d CLL. By univariable 
analysis, both homCD49dpos and bimCD49d had a significantly increased hazard of death 
(HR=3.18, 95% CI 2.41-4.19, and HR=2.37, 95% CI 1.71-3.3, respectively) compared to 
homCD49dneg patients (HR= 1.0, reference; Table 1). By Cox analysis for OS, both homCD49dpos 
and bimCD49d  remained independent predictors after adjusting for Rai stage, age, IGHV mutation 
status, del17p, del11q, TP53 and NOTCH1 mutation status in a model that not included B2M (Table 
1, model I, n=1,045) or included B2M (Table 1, model II, n=753). The same was observed in 
multivariable models considering TP53 disruption instead of del17p and TP53 mutations 
(Supplemental Table 7). 
 
Comparable results were obtained in a Cox analysis for TFS. Again, homCD49dpos and bimCD49d 
had an increased risk of being treated in models that either included B2M (n=831) or not included 




Finally, we compared the prognostic power of CD49d considered either as dichotomous according 
to the canonical 30% cut-off, or merging homCD49dpos plus bimCD49d CLL, both in univariable 
analysis and in the context of multivariable analyses that included Rai stage, age, IGHV and TP53 
mutation status (Supplemental Table 9). In both analyses, merging homCD49dpos and bimCD49d 
CLL outperformed the 30% cut-off (C-index=0.63, 95% CI 0.59-0.67  vs 0.64, 95% CI 0.60-0.67, 
p<0.001) and improved the prognostic power of the Cox model (C-index=0.799, 95% CI 0.748-
0.809 vs 0.803, 95% CI 0.750-0.814, p<0.001). Of note, bimCD49d cases that would have been 
mis-assigned to a low risk group accounted for 9% of cases, corresponding to 147 cases in our 
cohort. 
 
CD49d bimodal expression correlated with shorter progression-free survival in ibrutinib 
treated patients 
The impact of CD49d bimodal expression on progression-free survival (PFS) under ibrutinib was 
evaluated in a cohort of 158 cases treated with ibrutinib in the context of an Italian multicenter NPP, 
with a median follow-up of 16 months (Supplemental Table 2). Among 158 patients, 29 were from 
a previous study of ours,33 with follow-up information here updated. In all cases, CD49d expression 
was evaluated before starting ibrutinib.  
 
The ibrutinib cohort was characterized by 39 (24.7%) bimCD49d and 119 (75.3%) homCD49d 
cases. Also in this context, the CD49d 30% cut-off split homCD49d but not bimCD49d CLL into 
two groups with different prognosis (Figure 4C and Supplemental Figure 13A). Moreover, 
bimCD49d cases displayed shorter PFS than homCD49dneg CLL (p=0.004), and no different PFS 
when compared to homCD49dpos CLL (Figure 4C). Consistently, homCD49dpos and bimCD49d 
CLL combined in a single group showed reduced PFS compared to homCD49dneg CLL (p= 0.0052, 
Supplemental Figure 13B). 
 
The prognostic impact of homCD49dpos/ bimCD49d CLL was then tested in multivariable analyses. 
HomCD49dpos/ bimCD49d CLL retained independent negative prognostic impact together with 
TP53 disruption and >1 previous therapies, both in a multivariable model that considered the whole 
cohort of ibrutinib-treated patients (n=158), and in a subgroup of R/R CLL (n=124) where 
information on other prognostic factors,34 was available (Table 2). 
 
We then verified if the proportion of CD49dpos cells varied over time during ibrutinib treatment in 
patients with bimCD49d expression. Two consecutive samples were available in 8 bimCD49d 
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cases, with a median time between the pre-ibrutinib and post-ibrutinib sample collection of 28 
months (range 8-50). In all cases, an increased proportion of CD49dpos cells emerged after treatment 
(p=0.0078, Figure 4D and Supplemental Figure 14). 
 
CD49d expression and CLL-IPI risk categories 
We finally tested if CD49d expression had an impact on overall survival prediction in the context of 
the risk categories identified by the international prognostic index (CLL-IPI).35 Complete data to 
score CLL cases according to the CLL-IPI were available in 878 patients from our cohort. The 
CLL-IPI was able to efficiently segregate CLL patients in four risk categories characterized by 
significantly different OS (Figure 5A). In the context of each risk category, we further split patients 
into two groups according to CD49d expression, considering homCD49dpos and bimCD49d CLL as 
a single group (CD49dpos/bimCD49d). CD49dpos/bimCD49d CLL showed reduced OS in all CLL-
IPI risk categories with the exception of the very high risk group, where the survival probability of 





This study was set out to investigate the functional and clinical implications of the bimodal 
expression of CD49d in CLL. The presence of CLL characterized by bimodal CD49d expression 
had been indicated in previous studies by us,20,21 but the frequency and the clinical impact of 
CD49d bimodal expression has never been addressed. Here, using a large cohort of patients, we 
showed that the frequency of CD49d bimodal cases accounted for ~20% of total cases. The 
CD49dneg and CD49dpos sub-populations from the large majority of these bimodal cases shared the 
same IGHV rearrangement, confirming a common clonal origin. 
 
CD49d in CLL is expressed at either very low or very high levels in most cases, with few cases 
displaying expression levels around the 30% cut-off. 1,2 This characteristic, associated with a low 
probability of misclassifying patients, is further emphasized by the results from the present study. 
Indeed, after sorting out CLL cases with CD49d bimodal expression, the frequency of CLL cases 
with 20-40% CD49d expression in the homCD49d group turned out to be even lower (from 6% to 
2%, i.e. 27/1,630, cases). 
 
The temporal stability, another important feature of CD49d expression,1,2,36 has been here 
confirmed, particularly in the context of CLL completely lacking CD49d, in line with the 
methylation-dependent regulation of CD49d expression.21 On the other hand, a fine-tune regulation 
of CD49d expression, observed in CLL cases with moderate to high CD49d expression, has been 
already reported in previous studies showing that microenvironmental stimuli are able to increase 
CD49d expression.20,37 Since our flow cytometry analyses, based on the acquisition of at least 
10,000 CLL events, could reach the 1% sensitivity, we cannot exclude the presence of lower 
percentages of CD49dpos cells in CLL grouped as homCD49dneg. However, in none of these cases 
with sequential samples available, a measurable CD49dpos clone emerged. At variance with what 
reported in homCD49d CLL cases, bimCD49d cases showed an overall increase of the CD49dpos 
sub-population after treatment, with a tendency towards a plateau subsequent to multiple lines of 
therapy. This observation may be explained by the selection of CD49dpos CLL cells that find 
protection from therapy and/or gain proliferative advantage in the context of microenvironmental 
niches.38 Consistently, the CD49dpos sub-population of bimodal cases was increased in the BM, 
which is a privileged site of relapse in CLL,39,40 compared to PB. Even though we had not the 
chance to analyse paired LN-derived samples from CD49d bimodal cases, the analysis of CD49d 
expression in the context of the proliferative fraction CXCR4low/CD5bright, which was indicated as 
the group of cells recently egressed from lymphoid tissues,16 highlighted a higher proportion of 
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CD49dpos cells compared to their paired fractions. Consistently, bimCD49d cases presented with 
LN involvement at diagnosis more frequently compared to homCD49dneg CLL, but less frequently 
than CD49dpos CLL, where baseline lymphadenopathy accounted for ~62% of cases, in line with 
previously reported data.10 In this context, it remains to be determined if bimCD49d CLL may be 
more prone than homCD49dneg CLL to develop lymphadenopathy during the course of the 
disease.10  
 
In keeping with the association with a CXCR4low/CD5bright phenotype,16 CD49dpos sub-populations 
also showed a higher proliferation potential than the CD49dneg counterpart. The reasons behind this 
phenomenon cannot be explained by the mere expression of CD49d, but rather can be sought in the 
preferential expression by the CD49dpos cells of other co-stimulatory molecules. Even though the 
present study has not addressed this issue, previous reports by our and other groups showed high 
correlation and close relationship between expression of CD49d and CD38,19,41-43 a molecule that 
was reported to label a subset enriched in proliferating cells within CLL clones, and associated with 
the risk of disease progression even when expressed in a sub-fraction of CLL cells.44,45 Moreover, 
here we corroborated our previous findings of a significant association between CD49dpos cells with 
trisomy 12 and NOTCH1 mutations,26,27 pointing to a possible role of NOTCH1 mutations in 
driving cell survival and proliferation in CD49dpos cells through NF-kB pathway activation.20,37  
 
Despite the higher proliferative capacity of the CD49dpos sub-populations observed in-vitro, 
CD49dneg and CD49dpos cells did not show different replicative histories in the majority of the 
investigated cases, pointing to a balanced proliferation rate in-vivo. However, a different telomerase 
activity between CD49dneg and CD49dpos cells can be hypothesized,46 and it cannot be ruled out that 
a different telomere shortening may occur in follow-up samples, as it was reported in CLL cases 
with clonal evolution.47 
 
In light of all previous considerations, it was not completely unexpected that bimCD49d CLL 
patients, even in the presence of a small CD49dpos sub-population, followed a clinical outcome 
similar to that of homCD49dpos patients in CLL cases treated with conventional chemo-
immunotherapy. Of note, both homCD49dpos and bimCD49d expression retained independent 
prognostic impact in multivariate models which included the main clinical and biological 
prognosticators.22 Consistently, the combination of homCD49dpos with bimCD49d CLL in one 





The negative prognostic impact of CD49d in the ibrutinib setting, was previously reported by us in 
CLL patients from two independent ibrutinib-treated cohorts.33 In the present study, we could 
confirm CD49d expression as a negative prognostic marker in patients treated with ibrutinib, and 
showed that both homCD49dpos CLL, and bimCD49d CLL experienced significantly shorter PFS 
than CD49dneg CLL. Moreover, the homCD49dpos and bimCD49d categories turned out both 
independent prognosticators in the context of multivariable models that included the main clinical 
and biological covariates with a clinical impact in the ibrutinib setting.34 Further validation studies 
with longer follow-up and larger cohorts of patients are needed to definitely validate CD49d as OS 
predictor in the context of target therapies. 
 
Our previous study showed that, after one year of ibrutinib treatment, the lymph node mass 
reduction was lower in CD49dpos compared to CD49dneg CLL.33 Consistently, the increasing 
proportion of the CD49dpos sub-population observed here in eight CLL cases with CD49d bimodal 
expression after ibrutinib treatment, strongly supports the hypothesis of a higher resistance to the 
treatment for CD49d expressing cells. In the light of these data it would be interesting to evaluate 
whether higher percentages of the CD49dpos sub-population could be found in tissue compartments 
other than PB. 
 
Overall, our data point to a potential relevant role of CD49d to clinical practice, also in the light of 
its ability to separate patients with different OS probability in the context of the CLL-IPI risk 
categories.35 In this regard, further validation studies are needed to test whether including the 
CD49d expression, either homogeneous or bimodal, in a comprehensive prognostic risk score may 
help to better stratify patients treated with chemoimmunotherapy or targeted therapy. 
 
In summary, in the present study we have reported for the first time the presence, among CLL, of 
~20% of cases characterized by CD49d bimodal expression. The CD49dpos cells from bimodal 
CD49d CLL displayed higher levels of proliferation compared to the CD49dneg cells, and were more 
highly represented in the BM compared to PB, and in CLL subsets enriched in proliferative cells. 
The higher proliferative capacity of CD49dpos cells was in keeping with the tendency of the 
CD49dpos sub-population to increase over time especially after therapy. In this regard, it is tempting 
to speculate that the CD49dpos sub-population, even if it represents a minority of the tumor, may 
support the progression of the entire clone. Indeed, from a clinical point of view, the presence of 
small cell CD49dpos populations consistently associated with bad prognosis, suggesting to merge 
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Figure 1. CD49d bimodal and homogeneous expression. (A-B) Histogram plots of CD49d 
expression (red) in two representative CLL cases with CD49d bimodal expression (A) and in two 
representative CLL cases with CD49d homogeneous expression (B). Grey histograms refer to 
unstained cells; (C-D) Relative percent frequency of CD49d expression in CLL with CD49d 
bimodal (C) and CD49d homogeneous (D) expression. 
 
Figure 2. CD49d expression over time. CD49d expression was evaluated in two sequential 
samples from 94 CLL cases with CD49d bimodal expression either untreated (n=52, A) or treated 
once between the samples (n=42, B); (C) Variation of the amount of CD49dpos cells in sequential 
samples from 13 CD49d bimodal CLL treated with 2 lines of therapy (n=3, dark symbols), 3 lines 
of therapy (n=6, green symbols) or 4 lines of therapy (n=4, red symbols); p values refer to the 
paired Wilcoxon test (A-B) and to the Bonferroni-corrected Student’s t-test (alpha=0.0125).  
 
Figure 3. Amount of CD49dpos cells in different tissue compartments and in intra-clonal 
populations from bimCD49d CLL. (A) Percent of CD49dpos cells in paired peripheral blood (PB) 
and bone marrow (BM) samples from 13 CLL cases with CD49d bimodal expression; (B) Amount 
of CD49dpos cells in intra-clonal sub-populations with variable reciprocal densities of CXCR4/CD5 
expression (CXCR4dim/CD5bright and CXCR4bright/CD5dim fractions) from 147 CLL cases with 
CD49d bimodal expression; p values refer to the paired Wilcoxon test.  
 
Figure 4. Clinical impact of CD49d bimodal expression in the context of 
chemoimmunotherapy and ibrutinib treatment. (A) Overall survival Kaplan-Meier curves of all 
bimCD49d CLL cases split in bimCD49dneg (grey curves) and bimCD49dpos (black curves) groups 
according to the 30% cut-off; (B) Overall survival Kaplan-Meier curves of CLL cases with bimodal 
CD49d expression (bimCD49d, red curves), homogeneous negative (homCD49dneg, grey curves) 
and homogeneous positive (homCD49dpos, black curves) CD49d expression; (C) Progression-free 
survival Kaplan-Meier curves of ibrutinib-treated CLL cases with bimodal CD49d expression 
(bimCD49d, red curve), neg (grey curve) and pos (black curve) homogeneous CD49d expression 
(homCD49d). (D) CD49d expression in two sequential samples from 8 CLL cases with CD49d 
bimodal expression treated with ibrutinib between samplings; p values refer to the log-rank test (A-





Figure 5. Clinical impact of CD49d expression in the context of CLL-IPI categories. (A) 
Overall survival Kaplan-Meier curves of CLL cases split in the four risk categories of the CLL 
international prognostic index; (B-E) Overall survival curves of CLL cases with homogeneous 
negative CD49d expression (homCD49dneg, grey curve) and the merging of homogeneous positive 
(homCD49dpos) and bimodal CD49d (bimCD49d) expression (black curve) in the context of the low 
risk (B), intermediate risk (C), high risk (D) and very high risk (E) categories of the CLL-IPI; p 
values refer to the log-rank test.
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Table 1. Cox regression analysis of overall survival. 







 cases HR 95% CI p HR 95% CI p HR 95% CI p 
homCD49dpos* 1,522 3.18 2.41-4.19 <0.0001 2.13 1.52-2.99 <0.0001 2.65 1.76-3.98 <0.0001 
bimCD49d† 1,522 2.37 1.71-3.30 <0.0001 2.12 1.44-3.12 0.0001 2.70 1.74-4.17 <0.0001 
age >65 1,522 3.16 2.46-4.06 <0.0001 4.05 2.96-5.54 <0.0001 3.72 2.55-5.44 <0.0001 
Rai stage II-IV 1,515 2.68 2.10-3.43 <0.0001 1.82 1.32-2.44 0.0001 n.i. n.i. n.i. 
UM IGHV 1,385 3.88 3.02-5.00 <0.0001 2.41 1.79-3.24 <0.0001 2.78 1.99-3.91 <0.0001 
del17p 1,407 4.81 3.29-7.03 <0.0001 n.i. n.i. n.i. 2.21 1.44-3.38 0.0003 
del11q 1,407 2.56 177-3.69 <0.0001 n.i. n.i. n.i. n.i. n.i. n.i. 
tri12 1,407 1.82 1.29-2.56 0.0006 2.32 1.64-3.29 <0.0001 0.65 0.43-0.98 0.0423 
TP53 mutated 1,253 3.04 2.23-4.16 <0.0001 2.41 1.79-3.24 <0.0001 n.i. n.i. n.i. 
NOTCH1 mutated 1,444 2.02 1.54-2.65 <0.0001 n.i. n.i. n.i. n.i. n.i. n.i. 
β2M >ULN 1,017 4.12 3.01-5.63 <0.0001 - - - 1.73 1.18-2.52 0.0048 
All factors used in univariable analyses were entered in the multivariable analysis;  
*homCD49dpos refers to CLL cases with >30% homogeneous expression of CD49d; †bimCD49d refers to CLL cases with 
bimodal expression of CD49d. 
Abbreviations: β2M, beta-2 microglobulin; CI, confidence interval; del, deletion; HR, hazard ratio; n.i., not included in the 
model after stepwise selection; tri, trisomy; ULN, upper limit of normal; UM, unmutated. 
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Table 2. Cox regression analysis for progression-free survival in ibrutinib-treated CLL. 
 Whole ibrutinib-treated cohort (n=158) 
Factor Univariable analysis Multivariable analysis* 
 HR  95% CI p HR 95% CI p 
CD49dpos† 3.03  1.34-6.87 0.0079 2.63  1.13-6.10 0.0242 
UM IGHV 1.71  0.75-3.88 0.199 - - - 
TP53 disruption 2.63  1.37-5.06 0.0038 2.10  1.06-4.14 0.0327 
Rai stage III-IV 2.43  1.31-4.49 0.0046 n.i. n.i. n.i. 
Lines of therapy >1‡ 4.49  2.39-8.45 <0.0001 4.80  2.54-9.08 <0.0001 
 R/R ibrutinib-treated CLL (n=124) 
Factor Univariable analysis Multivariable analysis§ 
 HR  95% CI p HR 95% CI p 
CD49dpos† 3.42  1.39-8.43 0.0075 3.41  1.32-8.79 0.0112 
UM IGHV 1.94  0.67-5.58 0.2191 - - - 
TP53 disruption 4.01  1.82-8.82 0.0006 3.06  1.34-6.97 0.0079 
Hemoglobin 
<110 g/L for women 
<120 g/L for men 
3.73  1.79-7.78 0.0004 - - - 
Rai stage III-IV 2.87  1.40-5.91 0.0041 - - - 
β2M >5 mg/L 1.09  0.44-2.68 0.8513 - - - 
LDH >ULN 2.14  1.05-4.40 0.0373 - - - 
Time from last therapy <24 
months 
1.98  0.90-4.38 0.0907 - - - 
Lines of therapy >1|| 5.08  2.34-11.03 <0.0001 6.68  2.91-15.35 <0.0001 
*All factors with a significant p value in univariable analyses were entered in the multivariable 
analysis;  
† CD49dpos cases were obtained by combining cases with >30% homogeneous CD49d expression 
and cases with CD49d bimodal expression. 
‡ comparison between 0-1 vs >1 lines of therapy. 
§Significant features for multivariate analysis were selected through a Cox LASSO (least absolute 
shrinkage and selection operator) regression, selecting variables with non-zero coefficient under the 
best lambda selected by the model (Tibshirani R, Stat Med 1997; 16:385);  
||comparison between 1 vs >1 lines of therapy. 
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